NCT05439057View on ClinicalTrials.gov

Effect of Remimazolam on Postoperative Nausea and Vomiting

NACompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Postoperative Nausea and Vomiting
Interventions
DRUG

Remimazolam

Remimazolam is infused at a rate of 0.3 mg/kg/hr from induction of anesthesia until 20 minutes before the end of operation.

DRUG

Control

Normal saline is infused at a rate of 0.3 ml/kg/hr from induction of anesthesia until 20 minutes before the end of operation.

Trial Locations (1)

Unknown

Sanggye Paik hospital, Seoul

All Listed Sponsors
lead

Inje University

OTHER